Brought to you by 
The Medicines Co. grants SciClone rights to sell two cardiovascular therapies in China
26 May 2021
Executive Summary
The Medicines Co. licensed SciClone Pharmaceuticals Inc. exclusive rights to sell two IV cardiovascular drugs in China--Angiomax (bivalirudin) and Cleviprex (clevidipine).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
The Medicines Co. grants SciClone rights to sell two cardiovascular therapies in China
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice